Clostridium butyricum NCU-27 and application thereof
The regulation of intestinal microbiota and short-chain fatty acid metabolism through Clostridium butyric acid NCU-27 solves the problem of insulin resistance after gastrectomy, significantly improves postoperative metabolic disorders and healing, and provides a safe and effective treatment plan.
Patent Information
- Application Number
- CN202411441082.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-16
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-10-16
AI Technical Summary
Patients often experience insulin resistance after gastrectomy, resulting in metabolic disorders, increased energy demand and poor healing. Existing treatments such as insulin injection have inconvenience and risk of hypoglycemia, and lack safe and effective prevention and treatment methods.
Clostridium butyric acid NCU-27 is used to regulate the intestinal microbiota and short-chain fatty acid metabolism, increase butyric acid production, and improve insulin resistance after gastrectomy, which may be achieved through the enterohepatic axis and mTORC1 signaling pathway.
It significantly reduced the fasting blood glucose and insulin levels in rats after surgery, improved glucose tolerance, increased liver glycogen content, regulated intestinal flora and signaling pathways, and provided a safe and effective insulin resistance treatment strategy.
Smart Images

Figure CN118956699A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedicine, and specifically relates to a Clostridium butyricum NCU-27 and an application thereof. Background Art
[0002] At present, comprehensive treatment with radical surgery as the main treatment mode for advanced gastric cancer. However, on the one hand, the removal of tumor lesions can improve the survival rate of patients; on the other hand, surgical trauma is a stressor. Due to local tissue inflammation and surgical reactive stress, a series of neuroendocrine reactions, mainly sympathetic nerve excitement and increased pituitary-adrenal cortex secretion, occur after surgery, causing postoperative metabolic disorders in gastric cancer patients. Insulin resistance is one of them. Its specific manifestation is that the patient's blood sugar increases after surgery, and the fasting serum insulin level also increases. This phenomenon is insulin resistance.
[0003] Studies have shown that insulin resistance exists in almost all surgeries, can occur within a few minutes of the start of surgery, and can last for several weeks. At the same time, studies have pointed out that the incidence of insulin resistance in patients after elective surgery in general surgery is low. The incidence of insulin resistance varies depending on the surgical site. For example, the incidence of insulin resistance after gastric cancer surgery is the highest, followed by colorectal cancer surgery. Insulin resistance reduces the effect of synthetic hormones in the body, and the body's catabolism is enhanced. At the same time, the high metabolic state during surgical stress increases the body's energy demand, but the glucose oxidation energy supply of tissue cells is insufficient, and the body's energy supply then turns to fat-based, fat mobilization and glycolysis increase, and protein decomposition accelerates. In summary, postoperative insulin resistance not only leads to increased catabolism, negative nitrogen balance, poor wound healing and increased infection rate, but especially after gastrectomy, the postoperative protein level decreases, gastrointestinal anastomosis edema and poor healing, leading to anastomotic fistula. In addition, it also affects the stability of the body's internal environment, which seriously affects the patient's postoperative recovery and prognosis.
[0004] At present, it is believed that the mechanism of postoperative insulin resistance is mainly that neuroendocrine and inflammatory factors directly or indirectly interfere with the insulin action pathway. For example, studies have found that under surgical stress, the body will produce some reverse regulatory hormones (such as glucagon, catecholamines, cortisol, etc.), which inhibit the normal effect of anti-insulin, and the inflammatory factors (such as TNF-α) produced by surgery can indirectly stimulate the secretion of insulin antagonist hormones or directly affect the insulin signal transduction pathway and the membrane transfer of glucose transporters (glucose trans-porters, GLUT)-4 to affect blood sugar, thereby leading to insulin resistance. However, most of the research on insulin resistance at home and abroad focuses on the discussion of diabetes, endocrine diseases and their mechanisms, while less attention is paid to insulin resistance after radical surgery for gastric cancer. The treatment mainly relies on symptomatic treatment such as preoperative carbohydrates and insulin hypoglycemia. On the one hand, patients are not willing to accept invasive operations through insulin injection for hypoglycemia, and the dosage is difficult to control, and it is easy to cause hypoglycemia in patients, increasing perioperative risks. Therefore, it is of great significance to explore safe and effective methods that can effectively prevent and treat insulin resistance after gastrectomy. Summary of the invention
[0005] The purpose of the present invention is to solve the deficiencies of the prior art and provide a Clostridium butyricum NCU-27 and its application, specifically adopting the following technical solutions: In a first aspect of the present invention, a strain of Clostridium butyricum NCU-27 is provided, wherein the Clostridium butyricum ( Clostridium butyricum )NCU-27 was deposited in the General Microbiological Center of China Microbiological Culture Collection Committee on July 22, 2024, with the address: No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, and the deposit number is CGMCC NO.31386. And the gene sequence of 16S rDNA of Clostridium butyricum NCU-27 is shown in SEQ ID No: 1.
[0006] SEQ ID No: 1:
[0007] The second aspect of the present invention provides the use of the above-mentioned Clostridium butyricum NCU-27 in the preparation of a drug for preventing, improving or treating insulin resistance after gastrectomy.
[0008] The third aspect of the present invention provides a biological preparation, wherein the active ingredient of the biological preparation includes Clostridium butyricum NCU-27.
[0009] The fourth aspect of the present invention provides the use of the above-mentioned biological preparation in the preparation of a drug for preventing, improving or treating insulin resistance after gastrectomy.
[0010] The fifth aspect of the present invention also provides a drug for preventing, improving or treating insulin resistance after gastrectomy, wherein the drug comprises Clostridium butyricum NCU-27.
[0011] As a further preferred embodiment, the above-mentioned medicine further includes a pharmaceutical excipient; more preferably, the above-mentioned pharmaceutical excipient is at least one of water, lactose, sodium chloride and glucose.
[0012] As a further preferred embodiment, the dosage form of the above-mentioned drug is powder, granule, capsule or tablet; more preferably, the drug is for oral administration.
[0013] The beneficial effects of the present invention are as follows: the present invention provides a strain of Clostridium butyricum NCU-27, which can be used to prepare a drug for preventing, improving or treating insulin resistance after gastrectomy. According to the data of the embodiments of the present invention, Clostridium butyricum NCU-27 improves postoperative IR in the gastrectomy SD rat model by regulating intestinal microbiota and short-chain fatty acid metabolism, especially increasing the production of butyrate. This improvement may be achieved through the gut-liver axis and the mTORC1 signaling pathway, providing a potential strategy for the future clinical use of probiotics and butyrate derivatives to treat postoperative IR. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figure 1 Shown is Clostridium butyricum ( Clostridium butyricum ) The results of the in vitro probiotic property determination of NCU-27; A is the growth curve diagram, B is the acid resistance property evaluation diagram, C is the bile resistance property evaluation diagram, D is the hemolysis test result diagram, EF is the drug sensitivity test result diagram, G is the antioxidant property evaluation diagram; H is the bacterial Gram staining diagram.
[0015] Figure 2 Shown is Clostridium butyricum ( Clostridium butyricum) Evaluation chart of NCU-27 on IR level after gastrectomy in SD rats; A is the fasting blood glucose level of each group of rats on the first day after surgery, B is the fasting insulin level of each group of rats on the first day after surgery, C is the insulin resistance index of each group of rats on the first day after surgery, D is the area under the curve of intraperitoneal glucose tolerance test of each group of rats on the second day after surgery, E is the fasting blood glucose level of each group of rats on the third day after surgery, F is the fasting insulin level of each group of rats on the third day after surgery, G is the insulin resistance index of each group of rats on the third day after surgery, and H is the liver glycogen content of each group of rats on the third day after surgery.
[0016] Figure 3 Shown is Clostridium butyricum ( Clostridium butyricum ) The results of NCU-27 on intestinal flora imbalance after gastrectomy in SD rats; A is the Shannon index, B is the Venn diagram, C is the principal coordinate analysis, D is the changes in the abundance of Firmicutes, Verrucomicrobia and Bacteroidetes at the phylum level, E is the changes in the abundance of Streptococcus, Akkermansia, Zurichella and Roseburia at the genus level, and F is the random forest analysis.
[0017] Figure 4 Shown is Clostridium butyricum ( Clostridium butyricum ) Effect of NCU-27 on fecal butyric acid level in SD rats after gastrectomy; A is the result of ZO-1 immunofluorescence staining in the colon of each group of rats, and BH are the levels of acetic acid, butyric acid, hexanoic acid, isobutyric acid, isovaleric acid, propionic acid and valeric acid in the feces of each group of rats.
[0018] Figure 5 The figure shows the effect of butyrate on the IR level of SD rats after gastrectomy; A is the fasting blood glucose level of each group of rats on the first day after surgery, B is the fasting insulin level of each group of rats on the first day after surgery, C is the insulin resistance index of each group of rats on the first day after surgery, D is the area under the curve of the intraperitoneal glucose tolerance test of each group of rats on the second day after surgery, E is the fasting blood glucose level of each group of rats on the third day after surgery, F is the fasting insulin level of each group of rats on the third day after surgery, G is the insulin resistance index of each group of rats on the third day after surgery, and H is the liver glycogen content of each group of rats on the third day after surgery.
[0019] Figure 6 Shown is Clostridium butyricum ( Clostridium butyricum )The mechanism of NCU-27 and butyrate on the postoperative IR level in SD rats model after gastrectomy; A is the mRNA expression levels of AMPK, JNK, ERK, Raptor, IRS1 and AKT in the liver of each group of rats after surgery detected by qPCR; B is the mRNA expression levels of Raptor, P in the liver of each group of rats after surgery Ser Representative images of protein expression of Raptor-IRS1, IRS1, P-AKT, AKT, and β-actin in the liver of each group of rats after surgery; C is the ratio of Raptor to β-actin in the liver of each group of rats after surgery; D is the ratio of PSer -IRS1 and IRS1; E is the ratio of P-AKT and AKT in the liver of each group of rats after surgery; F is the ratio of GLUT4 and β-actin in the liver of each group of rats after surgery; G is the representative image of the protein expression of GLUT4, G6pase, Pepck, GYS2 and β-actin in the liver of each group of rats after surgery; H is the ratio of G6pase and β-actin in the liver of each group of rats after surgery; I is the ratio of Pepck and β-actin in the liver of each group of rats after surgery; J is the ratio of GYS2 and β-actin in the liver of each group of rats after surgery.
[0020] Figure 7 The figure shows the effect of mTORC1 agonist and inhibitor on Clostridium butyricum NCU-27 and butyric acid in improving the IR level of SD rats after gastrectomy; wherein, A is the fasting blood glucose level of rats in each group on the first day after surgery, B is the fasting insulin level of rats in each group on the first day after surgery, C is the insulin resistance index of rats in each group on the first day after surgery, D is the area under the curve of the intraperitoneal glucose tolerance test of rats in each group on the second day after surgery, E is the fasting blood glucose level of rats in each group on the third day after surgery, F is the fasting insulin level of rats in each group on the third day after surgery, G is the insulin resistance index of rats in each group on the third day after surgery, and H is the liver glycogen content of rats in each group on the third day after surgery.
[0021] Figure 8 The figure shows the effect of mTORC1 agonists and inhibitors on the mechanism of Clostridium butyricum NCU-27 and butyric acid on the IR level of SD rats after gastrectomy; A is the expression of Raptor and P in the liver of each group of rats after surgery. Ser A is a representative image of the protein expression of Raptor-IRS1, IRS1, P-AKT, AKT, and β-actin in the liver of each group of rats after surgery; C is the ratio of Raptor to β-actin in the liver of each group of rats after surgery Ser -IRS1 and IRS1 ratio; D is the ratio of P-AKT and AKT in the liver of each group of rats after surgery; E is the representative image of the protein expression of GLUT4, G6pase, Pepck, GYS2 and β-actin in the liver of each group of rats after surgery; F is the ratio of GLUT4 and β-actin in the liver of each group of rats after surgery; G is the ratio of G6pase and β-actin in the liver of each group of rats after surgery; H is the ratio of Pepck and β-actin in the liver of each group of rats after surgery; I is the ratio of GYS2 and β-actin in the liver of each group of rats after surgery. DETAILED DESCRIPTION
[0022] The following will be combined with the embodiments and drawings to clearly and completely describe the concept, specific structure and technical effects of the present invention, so as to fully understand the purpose, scheme and effect of the present invention. It should be noted that the embodiments and features in the embodiments of this application can be combined with each other without conflict.
[0023] Example 1 Clostridium butyricum ( Clostridium butyricum ) Screening of NCU-27 and related experiments 1. Material collection: Fresh feces were collected from normal healthy men and stored in sterile centrifuge tubes containing 50% glycerol. The collected feces samples were immediately diluted and spread on plates.
[0024] 2. Isolation, identification and evaluation of Clostridium butyricum: For fresh feces, TSB, LB, MRS, RCM, and BSM culture media were used for microbial isolation, and the isolated strains were then cultured in liquid culture. The genes of the strains were then extracted, and their 16S rDNA fragments were amplified using designed primers. The amplified 16S rDNA fragments were sequenced, and their sequence was shown in SEQ ID No: 1. The sequencing results were compared with the NCBI database information to determine the species classification of the strains.
[0025] One of the strains was identified as Clostridium butyricum NCU-27 through colony morphology, bacterial morphology and molecular biology methods.
[0026] Example 2 Clostridium butyricum ( Clostridium butyricum )In vitro probiotic properties of NCU-27 (1) Growth curve The probiotic Clostridium butyricum NCU-27 was incubated at 37°C for 24 h using anaerobic culture reinforced Clostridium medium (RCM, LA4360, Solarbio, China). The optical density (OD600 nm) of the bacterial suspension at each time point was determined by spectrophotometry, and the bacterial concentration was determined by plate counting method. The bacterial growth curve was drawn ( Figure 1 The results showed that Clostridium butyricum NCU-27 had strong growth characteristics under anaerobic conditions at 37°C, reaching the logarithmic growth phase in 4 hours and the plateau phase in 14 hours, with an OD600 nm of 2.06.
[0027] (2) Acid resistance test Take 10 mL of Clostridium butyricum cultured for 14 hours, centrifuge at 3000rpm for 10 minutes, discard the supernatant, wash twice with PBS, resuspend the bacteria in RCM medium, adjust the pH to 2.0, 3.0, 5.0, 7.0 with hydrochloric acid, and culture in an anaerobic incubator at 37℃ for 2 hours. Take 100μL of each dilution with PBS and spread on RCM agar plate for live bacteria count. The results are as follows Figure 1 As shown in B, and by Figure 1 As shown in Figure B, Clostridium butyricum NCU-27 showed high adaptability at different pH values (2.0, 3.0, 5.0 and 7.0). In particular, at pH = 7, the number of surviving bacteria was the highest, at 1.6 × 10 8 CFU / mL.
[0028] (3) Bile salt tolerance test Take 10 mL of Clostridium butyricum cultured for 14 h, centrifuge at 3000 rpm for 10 min, discard the supernatant, wash twice with PBS, resuspend the bacteria in RCM medium and add 0.3%, 0.2%, and 0.1% bile salts, culture in an anaerobic incubator at 37 °C for 2 h, take 100 μL of each dilution with PBS and spread on RCM agar plates for viable bacteria count. The results are as follows Figure 1 As shown in C, and by Figure 1 As shown in C, Clostridium butyricum NCU-27 has a strong tolerance to bile salts. Even at a bile salt concentration of 0.3%, the number of surviving bacteria is still as high as 7.0×10 7 CFU / mL.
[0029] (4) Hemolysis test Take 10 mL of Clostridium butyricum cultured for 14 hours, take 20 μL and inoculate it on a blood agar plate containing 5% sheep blood, and culture it in an anaerobic incubator at 37 ℃ for 24 hours. Use Staphylococcus aureus (ATCC25923) as a positive control, and perform a hemolysis test on Clostridium butyricum NCU-27 to observe and measure the diameter of the transparent hemolysis zone. The results are as follows Figure 1 As shown in D in Figure 1 As shown in D, Clostridium butyricum NCU-27 has no hemolytic ring, while the positive control group (Staphylococcus aureus) has an obvious hemolytic ring.
[0030] (5) Drug sensitivity test After taking 30 μL of the activated Clostridium butyricum NCU-27 bacterial solution twice and applying it on the RCM agar plate, stick the drug-sensitive paper on the surface of the agar plate and incubate it in an anaerobic incubator at 37°C for 16 h-18 h, measure and record the diameter of the inhibition zone. Figure 1 E- Figure 1 As shown in F, and by Figure 1 E- Figure 1It can be seen from the F in the figure that in the antimicrobial sensitivity test, the average inhibition zones of Clostridium butyricum NCU-27 to erythromycin (EM), penicillin (PEN), ciprofloxacin (CIP), ampicillin (AMP), lincomycin (MY), ceftriaxone (CTR), gentamicin (GEN), chloramphenicol (CAP) and tetracycline (TET) were 1.77 cm, 3.23 cm, 1.20 cm, 4.37 cm, 0.60 cm, 2.80 cm, 0.70 cm, 3.33 cm and 4.37 cm, respectively, while it showed resistance to compound sinomethoxazole (SXT). These results confirmed that Clostridium butyricum NCU-27 is a probiotic strain with excellent characteristics.
[0031] (6) Antioxidant test The Clostridium butyricum NCU-27 bacterial suspension activated twice was taken respectively, filtered through a 0.22 μm sterile filter membrane to retain the culture supernatant for subsequent determination.
[0032] a. DPPH free radical scavenging ability Add bacterial culture supernatant to DPPH methanol solution (0.2 mmol / L), react at room temperature in the dark for 30 min, and measure OD517. Calculate by the formula: Clearance = [1 - A517 (sample) - A517 (control) / A517 (blank)] × 100%.
[0033] b. Hydroxyl radical (·OH) scavenging ability Mix FeSO4 solution (2 mmol / L), H2O2 (6 mmol / L), salicylic acid (6 mmol / L) and bacterial culture supernatant, let stand at room temperature for 30 min, and then measure OD510. Calculate by the formula: Clearance = [1- A510 (sample) / A510 (control)] × 100%.
[0034] c. Superoxide radical (O 2- ) Clearing ability Mix Tris-HCL solution (150 mmol / L, pH = 8), pyrogallol solution (1.2 mmol / L) and bacterial culture supernatant, react at room temperature for 30 min, and measure OD330. Calculate by the formula: Clearance = [1-(A11 - A10) / (A01 -A00)] × 100%.
[0035] Among them: A00: does not contain sample and pyrogallol; A01: does not contain sample, contains pyrogallol A10: Contains sample but not pyrogallol; A11: Contains sample and pyrogallol d. Fe 2+Chelating ability Mix 0.4% ferrous sulfate solution and bacterial culture supernatant by inversion, then add 1% VC solution and NaOH solution (0.2mol / L), react at room temperature for 20 minutes, then add 10% trichloroacetic acid, centrifuge at 4℃, 6000 rpm / min for 10 minutes to remove protein, and take the supernatant. Mix the supernatant with 0.1% o-phenanthroline, react at room temperature for 10 minutes, and measure OD546. Calculate by the formula: Chelating capacity = [A546 (blank) - A546 (sample) / A546 (blank)] × 100%.
[0036] e. Total reducing power Mix PBS (pH = 6.6), 1% K3[Fe(CN)6] solution and bacterial culture supernatant, invert and mix, react at 50℃ for 2min. Then add 10% trichloroacetic acid solution, add deionized water and 0.1% FeCl3 solution to the mixture, let it stand for 10 min, and measure OD700.
[0037] The above experimental results are as follows Figure 1 As shown in G in Figure 1 As shown in G, Clostridium butyricum NCU-27 has a strong affinity for DPPH, •OH and •O 2- The scavenging capacity of Fe 2+ The chelating capacity is 10.35%, and the total reducing capacity is OD 700 nm is 1.09.
[0038] (7) Gram staining In a sterile environment, use an inoculation loop to take the bacterial solution and spread it on a glass slide. After making the slide, perform Gram staining and observe the morphology of the bacteria under a microscope. The bacteria are straight rod-shaped or slightly curved, single or paired, short chains, and have spores (such as Figure 1 ).
[0039] Example 3 Clostridium butyricum Clostridium butyricum )Study on the effect of NCU-27 on improving insulin resistance in SD rats after gastrectomy 1. Establishment, grouping and treatment of the gastrectomy SD rat animal model Modeling: Rats were fasted for 12 hours before surgery, but not water. Ensure adequate anesthesia before surgery, and shave and disinfect the surgical area. Make a midline incision of about 3 cm in the abdomen and expand the incision with a retractor. Turn up the left lobe of the liver, clamp the stomach body and pull it out of the abdominal cavity, and protect it with wet gauze. Cut the ligaments, free the lesser curvature, greater curvature of the stomach and the lower esophagus, and ligate the left gastroepiploic vessels. Cut the duodenum 0.5 cm proximal to the pylorus, cut the esophagus 0.5 cm above the cardia, and disinfect the incision. Anastomose the lower end of the esophagus with the duodenum, stop bleeding and check the suture. Clean the abdominal cavity, suture the incision and disinfect it. After surgery, inject 20 mL of normal saline, keep warm for resuscitation, and put it back in the cage after waking up.
[0040] Grouping: ① Model (M) group: 4 weeks before surgery, 1 mL of normal saline was gavaged daily; ② Clostridium butyricum (CB) group: 4 weeks before surgery, 1 mL of 1×10 8 CFU / mL Clostridium butyricum liquid was gavaged intragastrically.
[0041] 2. Comparison of fasting blood glucose and fasting insulin levels in rats of each group Fasting blood glucose (FBG) and fasting insulin (FINS) were measured on the first and third days after surgery. Biochemical analysis: Serum insulin and liver glycogen levels were measured using commercially available enzyme-linked immunosorbent assay (ELISA) kits (ELISA, China). Fasting blood glucose (FBG) was measured using a blood glucose meter (Sinocare, China).
[0042] The results of serological parameters of SD rats after surgery are as follows Figure 2 A- Figure 2 B and Figure 2 E- Figure 2 As shown in F, and by Figure 2 A- Figure 2 B and Figure 2 E- Figure 2 As shown in F, compared with the M group, the fasting blood glucose (FBG) level and fasting insulin (FIns) level in the CB group were significantly lower on the 1st and 3rd day after surgery (P<0.05).
[0043] 3. Comparison of insulin resistance in rats of each group Insulin resistance index (HOMA-IR) = fasting insulin level (uIU / mL) × fasting blood glucose level (mmol / L) / 22.5 The results of the insulin resistance index are as follows Figure 2 C and Figure 2 As shown in G, Figure 2 C in and Figure 2 As shown in G, compared with the M group, the insulin resistance index of the CB group was significantly reduced on the 1st and 3rd days after surgery (P<0.05).
[0044] Intraperitoneal glucose tolerance test (IPGTT) (2nd day after surgery): Rats were fasted for 12 h and then intraperitoneally injected with 40% glucose solution (5 mL / kg). Blood glucose levels were measured at 0, 15 min, 30 min, 60 min, and 120 min after fasting and glucose loading. IPGTT curves were drawn based on the results, and the area under the curve (AUC) was calculated = (0 min glucose + 2 × 30 min glucose + 3 × 60 min glucose + 2 × 120 min glucose) / 4.
[0045] The results are as follows Figure 2 As shown in D in Figure 2 As shown in D, the glucose tolerance of the CB group was significantly improved compared with that of the M group (P<0.001).
[0046] 4. Comparison of liver tissues of rats in each group Quantitative detection of liver glycogen: using Elisa kit The results are as follows Figure 2 As shown in H in Figure 2 The H in the figure showed that the liver glycogen content in the CB group was significantly higher than that in the M group on the third day after surgery (P<0.001). The experimental results showed that Clostridium butyricum NCU-27 played a key role in improving IR after gastrectomy in SD rats.
[0047] 5. Comparison of intestinal flora differences between rats in the M and CB groups - 16S rDNA sequencing We further explored the potential mechanism of Clostridium butyricum NCU-27 in improving IR after gastrectomy in SD rats. First, 16S rDNA gene sequencing was used to compare the changes in the intestinal microbiota of the two groups of SD rats after surgery. Figure 3 A- Figure 3 As shown in C, the results show that there is no significant difference in the α diversity index (including Shannon index) between the two groups of rats. It is worth noting that the principal coordinate analysis showed that there was a significant difference in the β diversity of the intestinal microbiota between the two groups (P<0.001). In addition, the Venn diagram also showed that there were differences in the intestinal microbiota between the two groups.
[0048] Subsequently, the composition of the intestinal microbiota of the two groups was further analyzed at the phylum and genus levels. Figure 3 D- Figure 3 As shown in E in Figure 3 D- Figure 3E in Figure 2 shows that at the phylum level, there was no significant difference in Firmicutes between the CB group and the M group, but the Verrucomicrobia and Bacteroidetes in the CB group increased significantly (P<0.05). At the genus level, compared with the M group, the Akkermansia, Zurichia, and Roseburia genera in the CB group increased significantly, while the Streptococcus genus decreased significantly (P<0.05).
[0049] In addition, the random forest analysis results showed that ( Figure 3 F in Figure ), at the genus level, Akkermansia, Bifidobacterium, Prevotella, and Roseburia were enriched in the CB group, while Streptococcus was enriched in the M group. The above results indicate that Clostridium butyricum NCU-27 can regulate the intestinal microbiota after gastrectomy in SD rats and increase the abundance of related butyrate-producing bacteria.
[0050] 6. Comparison of intestinal mucosal barrier permeability of rats in each group The colon tissues of mice in each group were collected, and the intestinal (colon) permeability protein: ZO-1 (tight junction protein) was detected by immunoassay.
[0051] Immunofluorescence: Paraffin-embedded sections were incubated with primary antibody against ZO-1 at 4°C overnight, followed by incubation with appropriate secondary antibodies and counterstained with DAPI, and fluorescence was visualized under a fluorescence microscope.
[0052] Immunofluorescence staining of intestinal tight junction protein-1 (ZO-1) was performed in the two groups of rats to evaluate the intestinal barrier function. Figure 4 As shown in A, the intervention of Clostridium butyricum NCU-27 increased the expression level of ZO-1 in the intestine of SD rats after gastrectomy.
[0053] 7. Targeted metabolomics detection - SCFA content detection (GC-MS) Metabolites in fecal samples were analyzed by gas chromatography-mass spectrometry (GC-MS). Feces (20 mg) were mixed with phosphoric acid solution and steel beads, ground, vortexed, sonicated, and centrifuged. 0.1 mL of the supernatant was taken, 0.5 mL of methyl tert-butyl ether (MTBE) was added, vortexed, sonicated, and centrifuged again, and the supernatant was collected. The analysis was performed using an Agilent 7890B GC-MS and a DB-5MS column.
[0054] In addition to the gut microbiota, targeted metabolomics analysis was performed on fecal samples from each group of rats to elucidate the metabolic changes of short-chain fatty acids (SCFAs) within the gut microbiota. Figure 4 B- Figure 4 As shown in H in Figure 4 B- Figure 4As shown in the H, compared with the M group, there was no significant change in the levels of acetic acid, hexanoic acid, isobutyric acid, isovaleric acid, propionic acid and valeric acid in the feces of the CB group; on the contrary, the butyric acid level in the CB group increased significantly (P<0.05).
[0055] Example 4 An experiment to explore the regulatory effect of Clostridium butyricum on insulin resistance after gastrectomy in SD rats mediated by butyrate 1. Model selection: The SD rat gastrectomy model was constructed in the same process as that in Example 3.
[0056] 2. Grouping: ① Blank control (C) group: 1 mL of normal saline was gavaged daily; ② Model (M) group: 1 mL of normal saline was gavaged daily 4 weeks before surgery; ③ Clostridium butyricum (CB) group: 1 mL of 1×10 8 CFU / mL Clostridium butyricum liquid was gavaged; ④ Sodium butyrate preparation (BA) group: sodium butyrate 1 mL, 400 mg / kg / d, gavage for 4 consecutive weeks.
[0057] 3. Comparison of fasting blood glucose and fasting insulin levels in rats of each group Fasting blood glucose (FBG) and fasting insulin (FINS) were measured on the first and third days after surgery. In order to investigate the effect of metabolite butyrate on IR levels in SD rats undergoing gastrectomy, this study established a gastrectomy model after SD rats were gavaged with sodium butyrate for 4 weeks. Figure 5 A- Figure 5 B and Figure 5 E- Figure 5 As shown in F, the fasting blood glucose level and fasting insulin level on the first and third days after surgery were significantly increased in group M compared with group C (P<0.05). However, the intervention of Clostridium butyricum NCU-27 and butyric acid significantly improved these parameters (P<0.05).
[0058] 4. Comparison of insulin resistance in rats of each group Insulin resistance index (HOMA-IR) = fasting insulin level (uIU / mL) × fasting blood glucose level (mmol / L) / 22.5 The results of the insulin resistance index are as follows Figure 5 C and Figure 5 As shown in G in Figure 5 C and Figure 5 As shown in G, the insulin resistance index on the first and third days after surgery was significantly increased in group M compared with group C (P<0.05). However, the intervention of Clostridium butyricum NCU-27 and butyric acid significantly improved these parameters (P<0.05).
[0059] Intraperitoneal glucose tolerance test (IPGTT) (2nd day after surgery): Rats were fasted for 12 h and then intraperitoneally injected with 40% glucose solution (5 mL / kg). Blood glucose levels were measured at 0, 15 min, 30 min, 60 min, and 120 min after fasting and glucose loading. IPGTT curves were drawn based on the results, and the area under the curve (AUC) was calculated = (0 min glucose + 2 × 30 min glucose + 3 × 60 min glucose + 2 × 120 min glucose) / 4.
[0060] The results of the intraperitoneal glucose tolerance test on the second day after surgery were as follows Figure 5 As shown in D, compared with group C, the glucose tolerance of group M was significantly decreased, while it was significantly improved under the intervention of Clostridium butyricum NCU-27 and butyric acid (P<0.05).
[0061] 5. Comparison of liver tissues of rats in each group Quantitative detection of liver glycogen: using Elisa kit for detection The results are as follows Figure 5 As shown in H in Figure 5 The H in the figure showed that the liver glycogen content in group M was significantly lower than that in group C on the third day after surgery, but it was significantly improved after intervention with Clostridium butyricum NCU-27 and butyric acid (P<0.05). These findings suggest that butyric acid can improve the IR level in SD rats after gastrectomy.
[0062] 6.q-PCR detection of changes in key proteins in insulin signaling pathways in liver tissues of rats in each group (AMPK, JNK, ERK, Raptor, IRS1, AKT) Total RNA was extracted from rat liver tissue using Trizol lysis reagent. Reverse transcription was performed using a reverse transcription kit, and real-time quantitative PCR was performed on a ViiA 7 real-time PCR system using TB Green® Premix Ex TaqTM kit to analyze mRNA expression levels. -△△Ct The data were processed by the PCR method, with β-actin as the internal reference gene.
[0063] To further explore the specific mechanism by which Clostridium butyricum NCU-27 and butyric acid improve postoperative IR in the gastrectomy SD rat model, PCR quantitative assay was used to evaluate the changes in related insulin signaling pathways in liver tissue. Figure 6 As shown in Figure A, the expression levels of AMPK, JNK, and ERK did not change significantly among the groups. However, compared with the other groups, the expression level of Raptor in group M was significantly increased, while the expression levels of IRS1 and AKT were significantly decreased (P<0.05).
[0064] 7. Western blot was used to detect the changes of key proteins in mTORC1 in the liver tissues of rats in each group (Raptor, P Ser -IRS1, IRS1, P-AKT, AKT, GLUT4, G6pase, Pepck, GYS2, β-actin) Tissue samples were treated with RIPA lysis buffer containing protease inhibitors, homogenized on ice, and centrifuged at 4°C to obtain the supernatant. Protein concentration was determined using a BCA protein quantification kit, and proteins were separated by SDS-polyacrylamide gel electrophoresis and transferred to a PVDF membrane. After blocking with skim milk powder solution, incubation with primary and secondary antibodies was performed, and finally protein visualization was performed using enhanced chemiluminescence solution.
[0065] The results are as follows Figure 6 B- Figure 6 As shown in J in the figure, the results show that compared with group C, the expression level of Raptor in group M was significantly higher, the phosphorylation level of IRS1 serine residues was significantly higher, and the phosphorylation level of AKT was significantly lower (P<0.05). In addition, the expression levels of GLUT4 and GYS2 in group M were significantly decreased, while the expression levels of G6pase and Pepck were significantly increased. These indicators were significantly improved after intervention with Clostridium butyricum NCU-27 and butyric acid (P<0.05). Based on the above results, it was found that Clostridium butyricum NCU-27 and butyric acid could improve the postoperative IR level in the gastrectomy SD rat model. In addition, the mTORC1 signaling pathway may be involved in this process.
[0066] Example 5 Study on Clostridium butyricum ( Clostridium butyricum )Regulates insulin resistance after gastrectomy in SD rats via butyrate-mediated mTORC1 pathway 1. Model selection: The SD rat gastrectomy model was constructed in the same process as that in Example 3.
[0067] 2. Grouping: ① Blank control (C) group: 1 mL of normal saline was gavaged daily; ② Model (M) group: 1 mL of normal saline was gavaged daily 4 weeks before surgery; ③ Clostridium butyricum (CB) group: 1 mL of 1×10 8 CFU / mL Clostridium butyricum liquid was gavaged; ④ sodium butyrate preparation (BA) group: sodium butyrate 1 ml, 400 mg / kg / d, for 4 consecutive weeks; ⑤ mTORC1 inhibitor treatment (RA) group: intraperitoneal injection of rapamycin solution 1 mg / (kg·d); ⑥ Clostridium butyricum preparation + mTORC1 agonist treatment (CBL) group: 4 weeks before surgery, daily with a concentration of 1 mL, 1×10 8CFU / mL Clostridium butyricum solution was gavaged + 1.5% L-leucine solution was given to drink freely; ⑦ Sodium butyrate preparation + mTORC1 agonist treatment group (BAL group): Sodium butyrate 1 mL was gavaged + 1.5% L-leucine solution was given to drink freely, 400 mg / kg / d, for 4 consecutive weeks.
[0068] 3. Comparison of fasting blood glucose and fasting insulin levels, insulin resistance and quantitative detection of liver glycogen in rats of each group (1) Fasting blood glucose (FBG) + fasting insulin (FINS) (1st day + 3rd day after surgery) (2) Insulin resistance index (HOMA-IR) (3) Intraperitoneal glucose tolerance test (IPGTT) (2nd day after surgery) (4) Quantitative detection of liver glycogen - Elisa The specific process of (1)-(4) above is consistent with the process in Example 3. The above test results are as follows Figure 7 A- Figure 7 As shown in the H in the figure, the fasting blood glucose level, fasting insulin level and insulin resistance index on the first and third days after surgery showed that mTORC1 agonists could offset the beneficial effects of Clostridium butyricum NCU-27 and butyric acid on the above indicators. In addition, the improvement effect of mTORC1 inhibitor alone on postoperative IR in SD rats was similar to that of Clostridium butyricum NCU-27 and butyric acid groups (P<0.05). The results of the intraperitoneal glucose tolerance test on the second day after surgery and the liver glycogen content on the third day after surgery also showed similar findings (P<0.05).
[0069] 4. Western blot was used to detect the changes of key proteins in mTORC1 in the liver tissues of rats in each group (Raptor, P Ser -IRS1, IRS1, P-AKT, AKT, GLUT4, G6pase, Pepck, GYS2, β-actin) The detection steps are the same as step 7 in Example 4, and the results are as follows Figure 8 A- Figure 8As shown in I, the results show that mTORC1 agonists counteracted the inhibitory effects of Clostridium butyricum NCU-27 or butyric acid on Raptor inhibition, the inhibitory effects on the phosphorylation level of IRS1 serine residues, and the stimulatory effects on the phosphorylation level of AKT, while the effects of mTORC1 inhibitors alone were similar to those of the CB and BA groups (P<0.05). In addition, compared with the M group, the expression levels of GLUT4 and GYS2 in the C, CB, BA, and RA groups were significantly increased, while the expression levels of G6pase and Pepck were significantly decreased. These changes could be counteracted by mTORC1 agonists (P<0.05). In summary, these data indicate that Clostridium butyricum NCU-27 and butyric acid play an important role in improving postoperative IR in the gastrectomy SD rat model through the gut-liver axis and mTORC1 signaling pathway.
[0070] From the above results, it can be seen that Clostridium butyricum NCU-27 provided by the present invention improves postoperative IR in the gastrectomy SD rat model by regulating intestinal microbiota and short-chain fatty acid metabolism, especially increasing the production of butyrate. This improvement may be achieved through the gut-liver axis and mTORC1 signaling pathway, providing a potential strategy for the future clinical use of probiotics and butyrate derivatives to treat postoperative IR.
[0071] Although the description of the present invention has been quite detailed and specifically describes several described embodiments, it is not intended to be limited to any of these details or embodiments or any particular embodiment, but should be regarded as providing a broad possible interpretation of these claims in view of the prior art by reference to the appended claims, thereby effectively covering the intended scope of the present invention. In addition, the above description of the present invention is based on the embodiments foreseeable by the inventor, and its purpose is to provide a useful description, and those non-substantial changes to the present invention that have not yet been foreseen may still represent equivalent changes to the present invention.
Claims
1. A Clostridium butyricum NCU-27, characterized in that The Clostridium butyricum ( Clostridium butyricum ) NCU-27 was deposited on July 22, 2024 at the General Microbiology Center of the China Culture Collection Administration, located at No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing, with the deposit number CGMCC NO.31386.
2. The Clostridium butyricum NCU-27 according to claim 1, characterized in that The gene sequence of 16SrDNA of Clostridium butyricum NCU-27 is shown in SEQ ID No:
1.
3. Use of the Clostridium butyricum NCU-27 according to any one of claims 1 to 2 in the preparation of a medicament for preventing, improving or treating insulin resistance after gastrectomy.
4. A biological agent, characterized in that Its active ingredients include Clostridium butyricum NCU-27.
5. Use of the biological preparation according to claim 4 in the preparation of a drug for preventing, improving or treating insulin resistance after gastrectomy.
6. A drug for preventing, improving or treating insulin resistance after gastrectomy, characterized in that: The drug includes Clostridium butyricum NCU-27.
7. The drug according to claim 6, characterized in that The medicine also includes pharmaceutical excipients.
8. The drug according to claim 7, characterized in that The pharmaceutical excipient is at least one of water, lactose, sodium chloride and glucose.
9. The drug according to any one of claims 6 to 8, characterized in that The dosage form of the medicine is powder, granule, capsule or tablet.
10. The drug according to claim 9, characterized in that The medicine is an oral medicine.
Citation Information
Patent Citations
Application of clostridium butyrate in preparation for prevention and treatment or adjuvant therapy of hyperglycemia
CN105769928A
Clostridium butyricum and application thereof
CN116286451A
Preparation method and application of clostridium butyricum exosome
CN118161536A
Insulin-sensitizing agent and butyrate-producing bacterium
US20240269197A1
Cited By
Preparation of cassia twig extract and application of cassia twig extract in treatment of endometriosis
CN121796465A
